US5021448A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist
Assignee: Novartis Corp
•
Filing: 1990-02-22
•
Granted: 1991-06-04
•
Expires: 2010-02-22
Abstract
Abstract A method of reducing serum uric acid and/or increasing renal clearance of uric acid in a mammal in need thereof comprising administering to such mammal a uricosuric effective amount of a thromboxane synthetase inhibitor, a thromboxane receptor antagonist, or both in a combined uricosuric effective amount is disclosed. Compositions having one or more of the foregoing in combination with one or more known uricosurics are also set forth.
Inventors
- 👤 Anthony J. Piraino
- 👤 Steven D. Saris
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 22:57
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K31/435; A61K31/44; A61P; A61P19/00; A61P19/06; A61P29/00; A61P39/00; A61P39/02; A61P43/00; A61P7/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
41 words
A method of treating or preventing hyperuricemia in a mammal in need thereof comprising administering to said mammal a hyperuricemia reducing or preventing effective amount of a) a thromboxane synthetase inhibitor; b) a thromboxane receptor antagonist; or both a) and b).
Claim 2
Independent Claim
41 words
A method of treating or preventing hyperuricemia in a mammal in need thereof comprising administering to said mammal a hyperuricemia reducing or preventing effective amount of a) a thromboxane synthetase inhibitor; b) a thromboxane receptor antagonist; or both a) and b).
Claim 3
Dependent Claim
24 words
The method of claim 1 wherein said thromboxane synthetase inhibitor is selected from 1-(7-carboxy heptyl)-3-methyl-2-(3-pyridyl)indole; 5-(5-carboxypentyl)-imidazo[1,5-a]pyridine; and 1-methyl-2-(3-pyridyl)-3(5-carboxypentyl)indole; and the pharmaceutically acceptable salts thereof.
Claim 4
Dependent Claim
14 words
The method of claim 2 wherein said pharmaceutically acceptable salt is the hydrochloride salt.
Claim 5
Dependent Claim
25 words
The method of claim 1 wherein a) a thromboxane synthetase inhibitor; or b) both a thromboxane synthetase inhibitor and a thromboxane receptor antagonist is administered.
Claim 6
Dependent Claim
18 words
The method of claim 4 wherein both a thromboxane synthetase inhibitor and a thromboxane receptor antagonist are administered.
Claim 7
Dependent Claim
18 words
The method of claim 1 wherein said thromboxane receptor antagonist is selected from 7-(3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo(2.2.1)hept-2-yl)-5-heptenoic acid and [p-(2-benzenesulfonamidoethyl)phenoxy]acetic acid.
Claim 8
Dependent Claim
106 words
A composition for the prevention or reduction of hyperuricemia comprising a) an effective hyperuricemia reducing or preventing amount of (i) a thromboxane synthetase inhibitor; (ii) a thromboxane receptor antagonist; or (iii) both a thromboxane synthetase inhibitor and a thromboxane receptor antagonist; and b) an effective amount of at least one of (i) a diuretic; (ii) a cytotoxic antineoplastic; (iii) a uricosuric not within paragraph (a); (iv) a xanthine oxidase inhibitor; or (v) an agent other than b)(i)-b(v) useful in the treatment of at least one condition selected from gout, gouty arthritis, gouty nephritis, eclampsia, polycythemia vera, myeloid metaplasia and other blood dyscrasias; or (vi) cyclosporin A.
Claim 9
Dependent Claim
106 words
A composition for the prevention or reduction of hyperuricemia comprising a) an effective hyperuricemia reducing or preventing amount of (i) a thromboxane synthetase inhibitor; (ii) a thromboxane receptor antagonist; or (iii) both a thromboxane synthetase inhibitor and a thromboxane receptor antagonist; and b) an effective amount of at least one of (i) a diuretic; (ii) a cytotoxic antineoplastic; (iii) a uricosuric not within paragraph (a); (iv) a xanthine oxidase inhibitor; or (v) an agent other than b)(i)-b(v) useful in the treatment of at least one condition selected from gout, gouty arthritis, gouty nephritis, eclampsia, polycythemia vera, myeloid metaplasia and other blood dyscrasias; or (vi) cyclosporin A.
Claim 10
Dependent Claim
23 words
The composition of claim 7 wherein said thromboxane synthetase inhibitor is selected from 1-(7-carboxy heptyl)-3-methyl-2-(3-pyridyl)indole; 5-(5-carboxypentyl)-imidazo[1,5-a]pyridine; 1-methyl-2-(3-pyridyl)-3-(5-carboxypentyl)indole; and a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
14 words
The composition of claim 8 wherein said pharmaceutically acceptable salt is the hydrochloride salt.
Claim 12
Dependent Claim
38 words
The method of claim 1 wherein said hyperuricemia is associated with a disease state selected from gout, gouty arthritis, gouty nephritis, pre-eclampsia, eclampsia, polycythemia vera, myeloid metaplasia, and other blood dyscrasias, or with the administration of cyclosporin A.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-06-03 | 1994-12-03 | 1995-06-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-06-03 | 1998-12-03 | 1999-06-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-06-03 | 2002-12-03 | 2003-06-04 | $7700.00 | Window Closed / Lapsed |